← All trials
NCT06698926
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 11, 2024
- Primary completion
- Mar 15, 2026
- Completion date
- Mar 15, 2026
- First posted
- Nov 21, 2024
- Last posted
- Nov 21, 2024
- Enrollment
- 112
- Arms / groups
- 14 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AbbVieLead sponsor
- AbbVieOfficial
- Calico Life Sciences LLCCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.